08.12.2017 04:48:10
|
New Drugs Approved In November
(RTTNews) - The process of drug development is challenging. Some drugs pass the FDA muster easily, while some face a host of hurdles before getting the official stamp of approval.
So far, 40 novel drugs have been approved for this year, compared to just 22 in 2016. Novel drugs are new molecular entities (NMEs) having chemical structures that have never been approved before.
Let's take a look at the drugs that crossed the regulatory finish line in November.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Valeant Pharmaceuticals International Inc.mehr Nachrichten
Keine Nachrichten verfügbar. |
Analysen zu Valeant Pharmaceuticals International Inc.mehr Analysen
Aktien in diesem Artikel
AstraZeneca PLC (spons. ADRs) | 72,50 | 0,69% |
|
Bristol-Myers Squibb Co. | 54,72 | 0,16% |
|
Dynavax Technologies Corp | 12,90 | -1,30% |
|
Heron Therapeutics Inc | 1,62 | 1,31% |
|
Merck Co. | 85,70 | 0,94% |
|
Ultragenyx Pharmaceutical Inc | 39,60 | 1,02% |
|